Drug intelligence / Profile preview

CPV-156

Development stage: Preclinical
Lead developer: University of Puerto Rico
Modality: Small Molecules

Overview

CPV-156 is a preclinical-stage cyclic thiosulfinate derivative developed by the University of Puerto Rico. It acts as an inhibitor of thioredoxin reductase (TrxR), an enzyme that is frequently overexpressed in various tumors and plays a key role in cell proliferation and redox regulation. In preclinical in vitro screenings, CPV-156 demonstrated significant cytotoxic activity against a panel of breast cancer cell lines, including MCF-7, ZR-75-1, BT-20, MDA-MB-468, SkBr-3, BT-474, and MDA-MB-231, by inhibiting cell growth by 72% to 95%.

Targets

TXNRD1 (Thioredoxin reductase 1)

Beyond the preview

Go deeper on CPV-156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPV-156.

Explore the full profile